Antibody Drug Conjugates Are Worth Watching, OptumRx Says

In its newest Drug Pipeline Insights Report, OptumRx highlighted recently approved or soon-to-be-approved drugs that might significantly impact payers and patients. In its latest quarterly report, though, the United...
0 Comments
© 2025 MMIT

Studies Paint Nuanced Picture of Insulin Out-of-Pocket Costs

Medicare enrollees this fall will be able to sign up for prescription plans that cap copayments for insulin at $35 a month. A recent Kaiser Family Foundation analysis shows that average annual out-of-pocket spending...
0 Comments
© 2025 MMIT

Pricey Cures Pose Reinsurance, Cost-Sharing Challenges

Genomic, curative drugs for chronic and terminal diseases are perhaps the most exciting new treatments in medicine. But even though these highly tailored therapies come to market with the potential to save costs for...
0 Comments
© 2025 MMIT

News Briefs

✦ This month, the federal government’s supply of remdesivir will run out, CNN reported. The antiviral drug is a palliative treatment for COVID-19 with documented clinical effectiveness, and is so far the only tr...
0 Comments
© 2025 MMIT

With One Drug-Supply Issue in Check, Another May Be Looming

While the COVID-19 pandemic led to worrying spikes in demand for certain drugs back in March and April — spurring PBMs to swiftly establish dispensing limits — that particular storm appears to have passed. Howev...
0 Comments
© 2025 MMIT

Scarcity, Geography Will Shape COVID-19 Vaccine Rollout

The rollout of a vaccine for SARS-CoV-2, the virus that causes COVID-19, is an unprecedented logistical challenge. So will be deciding who gets it: experts say that the initial vaccine supply will not be large enoug...
0 Comments
© 2025 MMIT

About 1,750 Medicare Rx Plans Join Fixed-Insulin-Copay Demo

The Trump administration on May 26 shared new details about a program that offers diabetic seniors access to a variety of insulin products for a maximum $35-per-month copay. More than 88 health insurers offering ...
0 Comments
© 2025 MMIT

Navitus Achieves Double-Digit Savings for New Clients in 2019

Navitus Health Solutions, a PBM that touts a 100% rebate pass-through model and a lowest-net-cost formulary, says it is seeing success in moderating total net cost per-member per-month (PMPM), particularly for new c...
0 Comments
© 2025 MMIT

CVS Reports Lowest Drug Trend in Years

CVS Health Corp.’s 2019 drug trend report shows a 1.4% overall trend, the lowest in five years, and said 41% of its commercial clients saw negative trend. Specialty drugs accounted for almost half of all spending ...
0 Comments
© 2025 MMIT

News Briefs

✦ A poll by the Kaiser Family Foundation found that the deepening economic crisis has made some patients struggle to afford their prescription medication, among other essentials. According to the poll, 8% of Ameri...
0 Comments
© 2025 MMIT